New drugs. Adverse reactions. I.
作者信息
Bateman D N, Chaplin S
机构信息
Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne.
出版信息
Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):761-4. doi: 10.1136/bmj.296.6624.761.
Abstract
摘要
相似文献
1
New drugs. Adverse reactions. I.
Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):761-4. doi: 10.1136/bmj.296.6624.761.
2
Postmarketing surveillance of adverse reactions to drugs.
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
3
Postmarketing surveillance of adverse reactions to drugs.
Br Med J (Clin Res Ed). 1984 Apr 14;288(6424):1155-6. doi: 10.1136/bmj.288.6424.1155.
4
Adverse reactions to new drugs.
Br Med J (Clin Res Ed). 1983 Mar 26;286(6370):1052-3. doi: 10.1136/bmj.286.6370.1052.
5
Post-marketing surveillance of new drugs.
J R Coll Gen Pract. 1987 Aug;37(301):337-8.
6
Spontaneous adverse drug reaction reports.
J R Soc Med. 1991 Nov;84(11):691-2.
7
Prescription-event monitoring and yellow cards.
Lancet. 1984 Jun 9;1(8389):1301. doi: 10.1016/s0140-6736(84)92486-3.
8
Monitoring of drugs after marketing.
J R Coll Gen Pract. 1983 Jul;33(252):438-41.
9
The yellow card: mark II.
BMJ. 1990 Dec 1;301(6763):1234. doi: 10.1136/bmj.301.6763.1234.
10
Postmarketing surveillance of adverse drug reactions: problems and solutions.
CMAJ. 1986 Jul 1;135(1):27-32.
引用本文的文献
1
Adverse effects of atypical antipsychotics in the elderly: a review.
Drugs Aging. 2006;23(12):937-56. doi: 10.2165/00002512-200623120-00002.
2
Recording previous adverse drug reactions--a gap in the system.
Br J Clin Pharmacol. 2001 Jun;51(6):623-6. doi: 10.1111/j.1365-2125.2001.01380.x.
3
The role of pharmacists in adverse drug reaction reporting.
Drug Saf. 1994 Jul;11(1):7-11. doi: 10.2165/00002018-199411010-00002.
4
A 12-month postmarketing surveillance study of nabumetone. A preliminary report.
Drugs. 1990;40 Suppl 5:80-6. doi: 10.2165/00003495-199000405-00021.
5
Clinical trials and clinical practice in the elderly. A focus on hypertension.
Drugs Aging. 1992 Mar-Apr;2(2):86-94. doi: 10.2165/00002512-199202020-00002.
本文引用的文献
1
Long-term safety of benoxaprofen.
J Rheumatol Suppl. 1980;6:100-7.
2
Incidence of arterial disease among oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study.
J R Coll Gen Pract. 1983 Feb;33(247):75-82.
3
Side effects of benoxaprofen.
Br Med J (Clin Res Ed). 1982 May 8;284(6326):1368-9. doi: 10.1136/bmj.284.6326.1368.
4
Fatal cholestatic jaundice in elderly patients taking benoxaprofen.
Br Med J (Clin Res Ed). 1982 May 8;284(6326):1372. doi: 10.1136/bmj.284.6326.1372.
5
Postmarketing surveillance of adverse reactions to drugs.
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
6
Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?
Br Med J (Clin Res Ed). 1983 Jan 22;286(6361):289-92. doi: 10.1136/bmj.286.6361.289.
7
Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.
Lancet. 1983 Oct 22;2(8356):926-30. doi: 10.1016/s0140-6736(83)90450-6.
8
Jaundice associated with the use of benoxaprofen.
Lancet. 1982 Apr 24;1(8278):959. doi: 10.1016/s0140-6736(82)91953-5.
9
Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study.
Lancet. 1981 Mar 7;1(8219):541-6.
10
Exfoliative dermatitis and practolol.
Lancet. 1972 May 20;1(7760):1130. doi: 10.1016/s0140-6736(72)91482-1.
Zotero 插件